The new data found that patients identified as low risk by the test received fewer biopsies and were less likely to be diagnosed later with high-grade prostate cancer.
Sysmex Gets Approval in Japan for Retinal Dystrophy Gene Panel
The next-generation sequencing panel identifies genetic mutations that cause inherited retinal dystrophy, which results in vision problems, including blindness.
Top Five Articles on 360Dx Last Week: FDA's Post-Pandemic Plans; DiaSorin, MeMed Deal; and More
Last week, readers were most interested in a story about the COVID pandemic's effects on how the FDA will evaluate in vitro diagnostics moving forward.
Invivoscribe, Complete Genomics Partner to Develop, Commercialize Oncology Biomarker Tests
The companies will collaborate to develop biomarkers tests for minimal residual disease (MRDs) in research and clinical setting using the DNBSeq sequencer.
The firm received FDA 510(k) clearance late last year for its 10-minute blood-based test that stratifies patients by their risk of developing sepsis.